Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly’s Alimta Gets UK Recommendation As Mesothelioma Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncologic is approved for use in three types of malignant pleural mesothelioma patients by Britain’s National Health Service.

You may also be interested in...

U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs

The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.

NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy

NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.

Lilly Alimta To Be Available In Two Weeks Following Five-Month Review

Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts